10.01 · Audit / Strategy & positioning
The hero says velocity. The proof says exposure.
The site leads with a strong line, then spends the rest of the page leaning on the wrong proof. "Buying media that sells" sets a sales-outcome promise. Most of what follows sells reach, channel breadth, and tenure instead. The first chapter of the audit is about that gap.
THE PROMISE · WHAT THE SITE CLAIMS TO DO
The hero line is the best line on the site.
"BUYING MEDIA THAT SELLS." Six words, sales-outcome, no hedge. It's the right thesis for a tenure-led performance agency, and it's the only place on the site that fully commits to outcome over activity. The sub-headline immediately softens it back to "Total Video Solutions That Drive Results", which is the same line every video-buying shop in the market runs.
Works
"Buying media that sells." Sales-first, no qualifier, owns a clear category position. The kind of line a CFO repeats from memory after one meeting.
Doesn't
"Total Video Solutions That Drive Results" The category, not the position. A CFO would have to look up what Total Video is, and "drive results" is the floor of every agency pitch.
THE PROOF · WHAT THE SITE ACTUALLY SHOWS
Three numbers that don't ladder back to the promise.
The homepage proof strip headlines 37+ years, $2B in stewardship, 40% lower CPMs. Tenure, scale, efficiency. None of them are sales-velocity claims. "Lower CPMs" is a buying-side win, not a sell-side win. To live up to the hero line the proof strip needs at least one metric that finishes the sentence: here is the sale we caused.
Tenure, scale, and efficiency are the proofs a buyer expects when the hero line is "we'll lower your CPM." When the hero is "we sell," the proof has to be sales.
10.01 · Strategy & positioningTHE AUDIENCE · WHO THE SITE IS BUILT FOR
Two readers, one page, no separation.
The homepage tries to speak to a performance CMO ("buying media that sells"), an SVP of Media ("40% lower CPMs"), and a brand founder ("scale your brand") in the same scroll. The portfolio confirms the actual book of business is DR-leaning consumer brands (Flex Seal, Pooph, Razor, TIDL, Zevo). That's a clear audience. The site doesn't name it.
- Implied core audience. DR-style consumer brands ($10M–$500M revenue) selling through Walmart / Target / Amazon, looking for predictable retail lift from TV + streaming + retargeting.
- Implied secondary. Healthcare / OTC / pharma via Diray Health, which gets a dedicated page but is barely cross-referenced from the main site.
- Stated audience. "Emerging Brands and Market Challengers" (homepage) — closest the site comes to naming an ICP. Generic, no qualifying numbers attached.
- What's missing. A clear "this is who we win for, this is who we don't" line. Without it, every visitor self-selects whether they fit, and most won't.
DIFFERENTIATION · WHY DIRAY VS. ALTERNATIVES
The four claims and the one that holds up.
The site offers four implicit answers to "why Diray instead of MNTN, Tatari, Vibe, or a holding-co agency." Three are easy to rebut. One is the actual moat.
SUB-BRAND · DIRAY HEALTH ISN'T LOADED INTO THE MAIN POSITION
A pharma vertical sitting in the navigation, not in the strategy.
Diray Health is a credible specialist play — HIPAA-compliant workflows, IQVIA + LiveRamp + Crossix data integration, NPI / specialty targeting for HCPs, names PureHealth Research, CloSYS, Celltrion, DermTech. The page reads like a focused pharma media practice. Then it goes to die in the nav. The main homepage doesn't mention Diray Health at all. A pharma marketer who lands on the parent site has to discover it as a top-nav item.
On the Diray Health page itself
Clear positioning, named data partners, regulatory cues, real client list. Reads like a category specialist who knows the buyer.
Everywhere else
The parent site does nothing to load the pharma vertical into its positioning. A CMO browsing Diray Media for the first time would not know healthcare is a real practice unless they click the nav.
FINDINGS · FIVE STRATEGIC GAPS
Five things to fix before the next visitor hits the page.
- Promise / proof mismatch. Hero says sales, proof shows tenure and CPM. Add at least one sales-velocity metric to the homepage proof strip, even anonymous (e.g., "+18% velocity vs. prior quarter, 12 DMAs, held-out control").
- Audience ICP is implicit, not named. Make one sentence on the homepage say "we win for DR-leaning consumer brands selling through Walmart, Target, Amazon, doing $10M–$500M." Loses the buyers who don't fit. Wins the ones who do, faster.
- Tenure under-leveraged. four decades and 10-year clients is the moat. Stop showing it as a stat. Narrate it: "the last brand we onboarded had a 6-year contract with a previous agency that left $X on the table." Tenure becomes a story, not a number.
- MediaINSIGHTS is unproven on the page. If it's a real differentiator, show three screenshots and one decision it drove. If it's not, stop calling it proprietary and stop treating it as one of the four core claims.
- Diray Health needs a parent-site mention. One paragraph + photo on the homepage. Loses no main-line ground, wins the pharma marketer who lands on the wrong page first.